Jones Financial Companies
AKBA icon

Jones Financial Companies’s Akebia Therapeutics AKBA Stock Holding History

Jones Financial Companies’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67K Hold
1,995
– – ﹤0.01% 4069
2025
Q4 		$3.21K Buy
1,995
+1,500
+303% +$3.14K ﹤0.01% 3675
2025
Q3 		$1.36K Hold
495
– – ﹤0.01% 3816
2025
Q2 		$1.81K Sell
495
-505
-51% -$1.39K ﹤0.01% 3489
2025
Q1 		$1.91K Hold
1,000
– – ﹤0.01% 3252
2024
Q4 		$1.9K Hold
1,000
– – ﹤0.01% 3012
2024
Q3 		$1.33K Buy
+1,000
New +$1.33K ﹤0.01% 2758

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Jones Financial Companies's AKBA Position: Q1 2026 in Review

Jones Financial Companies held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 1,995 shares worth $2.67K. The position accounts for ﹤0.01% of the portfolio, ranked #4069.

Jones Financial Companies first reported a position in AKBA in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.21K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Jones Financial Companies held 1,995 shares of Akebia Therapeutics worth $2.67K as of Q1 2026.
  • Jones Financial Companies left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4069 holding.
  • Jones Financial Companies first reported a position in Akebia Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Jones Financial Companies's Akebia Therapeutics position peaked at $3.21K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.